These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Safety of mTOR inhibitors in adult solid organ transplantation. Ventura-Aguiar P; Campistol JM; Diekmann F Expert Opin Drug Saf; 2016; 15(3):303-19. PubMed ID: 26667069 [TBL] [Abstract][Full Text] [Related]
6. A drug safety evaluation of everolimus in kidney transplantation. Holdaas H; Midtvedt K; Åsberg A Expert Opin Drug Saf; 2012 Nov; 11(6):1013-22. PubMed ID: 22954349 [TBL] [Abstract][Full Text] [Related]
7. The metabolic and toxicological considerations for immunosuppressive drugs used during pancreas transplantation. Rangel EB Expert Opin Drug Metab Toxicol; 2012 Dec; 8(12):1531-48. PubMed ID: 22978385 [TBL] [Abstract][Full Text] [Related]
8. A comprehensive update of the metabolic and toxicological considerations for immunosuppressive drugs used during pancreas transplantation. Vidigal AC; de Lucena DD; Beyerstedt S; Rangel ÉB Expert Opin Drug Metab Toxicol; 2023; 19(7):405-427. PubMed ID: 37542452 [TBL] [Abstract][Full Text] [Related]
9. Late Conversion to Sirolimus or Everolimus After Pancreas Transplant. Marcella-Neto R; de Sá JR; Melaragno CS; Gonzalez AM; Salzedas-Neto A; Linhares MM; Medina-Pestana JO; Rangel ÉB Transplant Proc; 2020 Jun; 52(5):1376-1379. PubMed ID: 32213293 [TBL] [Abstract][Full Text] [Related]
11. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity. Tönshoff B; Höcker B Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497 [TBL] [Abstract][Full Text] [Related]
12. Sirolimus and everolimus in kidney transplantation. Moes DJ; Guchelaar HJ; de Fijter JW Drug Discov Today; 2015 Oct; 20(10):1243-9. PubMed ID: 26050578 [TBL] [Abstract][Full Text] [Related]
13. Immunological Results of Long-Term Use of Mammalian Target of Rapamycin (mTOR) Inhibitors and Its Effects on Renal Graft Functions. Tanrısev M; Ayna Kılıçaslan T; Çolak H; Ersan S; Yılmaz B; Alp A; Tuğmen C; Sevgili BE Ann Transplant; 2021 Sep; 26():e932434. PubMed ID: 34531361 [TBL] [Abstract][Full Text] [Related]
14. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus. Sánchez-Fructuoso AI; Ruiz JC; Pérez-Flores I; Gómez Alamillo C; Calvo Romero N; Arias M Transplant Proc; 2010 Oct; 42(8):3050-2. PubMed ID: 20970607 [TBL] [Abstract][Full Text] [Related]
15. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes. Shihab F; Christians U; Smith L; Wellen JR; Kaplan B Transpl Immunol; 2014 Jun; 31(1):22-32. PubMed ID: 24861504 [TBL] [Abstract][Full Text] [Related]
16. Conversion From Calcineurin to Mammalian Target of Rapamycin Inhibitors in Liver Transplantation: A Meta-Analysis of Randomized Controlled Trials. Glover TE; Watson CJ; Gibbs P; Bradley JA; Ntzani EE; Kosmoliaptsis V Transplantation; 2016 Mar; 100(3):621-9. PubMed ID: 26636736 [TBL] [Abstract][Full Text] [Related]